Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

739.57
-2.5500-0.34%
Post-market: 739.570.00000.00%19:30 EDT
Volume:500.29K
Turnover:367.35M
Market Cap:76.14B
PE:18.29
High:744.50
Open:742.12
Low:723.65
Close:742.12
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:0.70
T/O Rate:0.51%
Dividend:3.64
Dividend Rate:0.49%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.40
PE(LYR):17.83

Loading ...

Nov 17, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 04, 2021

Major Issues Report

8-K - Current report
Nov 04, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Sep 16, 2021

Major Issues Report

8-K - Current report
Aug 05, 2021

Major Issues Report

8-K - Current report
Aug 05, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jun 16, 2021

Major Issues Report

8-K - Current report
May 06, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 06, 2021

Major Issues Report

8-K - Current report
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 08, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 08, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 05, 2021

Major Issues Report

8-K - Current report
Feb 01, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 15, 2021

Major Issues Report

8-K - Current report
Jan 11, 2021

Major Issues Report

8-K - Current report
Jan 05, 2021

Major Issues Report

8-K - Current report
Dec 07, 2020

Correspondence

CORRESP [Cover] - Correspondence
Nov 05, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]